

July 31, 2025

**BSE Limited**

The Listing Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> Floor, Dalal Street  
Fort, Mumbai 400 001  
Maharashtra, India

BSE Scrip Code: 544309

**National Stock Exchange of India Limited**

The Listing Department  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051  
Maharashtra, India

NSE Symbol: IKS

Dear Sir/Ma'am,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Outcome of the Board Meeting held on July 31, 2025.**

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”) and SEBI Master circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, we hereby inform that the Board of Directors of the Company at its meeting held today, i.e., July 31, 2025, *inter alia*, approved the following:

**1. Financial Results:**

The unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2025 (“**Financial Results**”). The Financial Results and the Limited Review Reports issued by Price Waterhouse Chartered Accountants LLP, Statutory Auditors of the Company on the said Financial Results of the Company are enclosed as “**Annexure – A**”.

**2. Inventurus Knowledge Solutions Inc, USA has designated Mr. Sachin Gupta as Global CEO:** The Board noted that Mr. Sachin Gupta has been designated as Global CEO of Inventurus Knowledge Solutions Inc, USA, wholly owned subsidiary of the Company.

**3. Appointment of Mr. Sachin Gupta as an Additional Director (Non-Executive, Non-Independent) of the Company:**

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has considered and approved appointment of Mr. Sachin Gupta (DIN: 02239277) as an Additional Director (Non-Executive, Non-Independent), liable to retire by rotation, w.e.f. August 1, 2025, subject to approval of shareholders.

Further, Mr. Sachin Gupta has also confirmed that he is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The disclosure under Regulation 30 read with Schedule III of the SEBI Listing Regulations for this matter is enclosed as “**Annexure – B**”.

#### 4. Resignation of Mr. Sachin Gupta as a Whole-time Director of the Company:

Mr. Sachin Gupta (DIN: 02239277), Whole-time Director of the Company has tendered his resignation from the position of the Whole-time Director of the Company with effect from close of business hours on July 31, 2025. The disclosure under Regulation 30 read with Schedule III of the SEBI Listing Regulations for this matter is enclosed as **"Annexure-C"**. The letter of resignation received from Mr. Sachin Gupta along with the confirmation that there are no material reasons for his resignation other than those mentioned therein is enclosed as **"Annexure-D"**.

#### 5. Appointment of Ms. Nithya Balasubramanin, CFO (KMP of the Company), as an Additional Director (Whole- time Director) on the Board of the Company:

The Board of Directors based on the recommendation of the Nomination and Remuneration Committee, has considered and approved appointment of Ms. Nithya Balasubramanian (DIN: 10664861) as an Additional Director (Whole-time Director) on the Board of the Company, for a term of 5 years from August 1, 2025 to July 31, 2030 (both days inclusive) subject to approval by the shareholders of the Company.

Further, Ms. Nithya Balasubramanian has also confirmed that she is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The disclosure under Regulation 30 read with Schedule III of the SEBI Listing Regulations for this matter is enclosed as **"Annexure – E"**

#### 6. Appointment of Mr. Garheng Albert Kong (DIN: 11218828), as Additional Director (Non-Executive, Independent) on the Board of the Company:

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has considered and approved appointment of Mr. Garheng Albert Kong (DIN: 11218828) as an Additional Director (Non-Executive, Independent) on the Board of the Company, for a term of 5 years from August 1, 2025 to July 31, 2030 (both days inclusive) subject to approval by the shareholders of the Company.

Further, Mr. Garheng Albert Kong has also confirmed that he is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The disclosure under Regulation 30 read with Schedule III of the SEBI Listing Regulations for this matter is enclosed as **"Annexure – F"**

#### 7. Appointment of Internal Auditor:

The Board of Directors, based on the recommendation of the Audit Committee, has considered and approved appointment of M/s. KKC & Associates LLP, Chartered Accountants (Firm Registration Number – 105146W/W100621) as Internal Auditor of the Company, for financial year 2025-26.

The disclosure under Regulation 30 read with Schedule III of the SEBI Listing Regulations for this matter is enclosed as **"Annexure – G"**



The Board Meeting commenced at 07:30 P.M. IST and concluded at 08:45 P.M. IST.

We request you to take the same on your records

Yours sincerely,  
For **Inventurus Knowledge Solutions Limited**

**Sameer Chavan**  
**Company Secretary and Compliance Officer**  
Membership No. F7211

Encl: As above

# Price Waterhouse Chartered Accountants LLP

## Review Report

To  
The Board of Directors  
**Inventurus Knowledge Solutions Limited**  
Building No. 5 & 6, Unit No. 801,  
8th Floor, Mindspace SEZ, Thane Belapur Road,  
Airoli, Navi Mumbai, Thane, Maharashtra 400708

1. We have reviewed the standalone unaudited financial results of Inventurus Knowledge Solutions Limited (the “Company”) for the quarter ended June 30, 2025, which are included in the accompanying ‘Statement of unaudited financial results for the quarter ended June 30, 2025 (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been digitally signed by us for identification purposes.

Attention is drawn to the fact that the financial results for the corresponding quarter ended June 30, 2024 as reported in the Statement have been approved by the Company’s Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West), Mumbai - 400 028  
T: +91 (22) 66697510

Registered office and Head office: 11-A Vishnu Digambar Marg, Sucheta Bhawan, New Delhi – 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)


# Price Waterhouse Chartered Accountants LLP

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP

Firm Registration Number: 012754N/N500016

PRIYANSHU  
DINESHKUMAR  
GUNDANA

 Digitally signed by PRIYANSHU  
DINESHKUMAR GUNDANA  
Date: 2025.07.31 20:38:27  
+05'30'

Priyansh Gundana

Partner

Membership Number: 109553

UDIN: 25109553BMOAXO2393

Place: Mumbai

Date: July 31, 2025



# Price Waterhouse Chartered Accountants LLP

## Review Report

To

The Board of Directors

**Inventurus Knowledge Solutions Limited**

Building No. 5 & 6, Unit No. 801,

8th Floor, Mindspace SEZ, Thane Belapur Road,

Airoli, Navi Mumbai, Thane, Maharashtra 400708

1. We have reviewed the consolidated unaudited financial results of Inventurus Knowledge Solutions Limited (the “Holding Company”), its subsidiaries (the Holding Company and its subsidiaries) hereinafter referred to as the “Group”), (refer Note 8 on the Statement) for the quarter ended June 30, 2025 which are included in the accompanying ‘Statement of unaudited financial results for the quarter ended June 30, 2025 (the “Statement”). The Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been digitally signed by us for identification purposes.

Attention is drawn to the fact that the consolidated financial results for the corresponding quarter ended June 30, 2024, as reported in these financial results have been approved by the Holding Company’s Board of Directors but have not been subjected to review.

2. This Statement, which is the responsibility of the Holding Company’s Management and has been approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting”, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (‘SRE’) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West), Mumbai - 400 028  
T: +91 (22) 66697510

Registered office and Head office: 11-A Vishnu Digambar Marg, Sucheta Bhawan, New Delhi – 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

# Price Waterhouse Chartered Accountants LLP

4. The Statement includes the results of the following entities:

Relationship	Entity name
Wholly owned Subsidiaries	Inventurus Knowledge Solutions Inc IKS Cares Foundation
Step down subsidiaries	Aquity Holdings Inc Aquity Solutions LLC Aquity Solutions India Private Limited Aquity Solutions Australia Pty Limited Aquity Canada ULC

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The interim financial information of one subsidiary reflects total revenues of INR 612.05 million, total net profit after tax of INR 68.06 million and total comprehensive income of INR 71.47 million, for the quarter ended June 30, 2025, as considered in the consolidated unaudited financial results. This interim financial information have been reviewed by other auditors and their reports dated July 31, 2025, vide which they have issued an unmodified conclusion, have been furnished to us by the other auditors and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

7. The consolidated unaudited financial results include the interim financial information of one subsidiary which have not been reviewed by their auditors, whose interim financial information reflect total revenue of INR Nil, total net loss after tax of INR 1.76 million and total comprehensive loss of INR 1.76 million for the quarter ended June 30, 2025, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, this interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For Price Waterhouse Chartered Accountants LLP  
Firm Registration Number: 012754N/N500016

PRIYANSHU  
DINESHKUMAR  
GUNDANA

Digitally signed by PRIYANSHU  
DINESHKUMAR GUNDANA  
Date: 2025.07.31 20:38:47  
+05'30'

Priyansh Gundana  
Partner  
Membership Number: 109553  
UDIN: 25109553BMOAXN9372  
Place: Mumbai  
Date: July 31, 2025

**Inventurus Knowledge Solutions Limited**  
**Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),**  
**Thane Belapur Road, Airoli, Navi Mumbai - 400 706, Thane, Maharashtra, India.**  
**CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205**  
**Website: www.ikshealth.com Email : investor\_relations@ikshealth.com**  
**Statement of unaudited financial results for the quarter ended June 30, 2025**

*(Amounts in INR ₹ Million, unless otherwise stated)*

Sr.No	Particulars	Consolidated				Standalone			
		For the quarter ended			For the year ended	For the quarter ended			For the year ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		unaudited	unaudited	unaudited	audited	unaudited	unaudited	unaudited	audited
<b>1 INCOME</b>									
	Revenue from operations	7,400.95	7,239.56	6,400.93	26,639.94	3,194.69	2,903.67	2,013.75	9,730.83
	Other income	31.13	32.61	35.81	389.98	21.49	16.92	10.75	153.17
	<b>Total income</b>	<b>7,432.08</b>	<b>7,272.17</b>	<b>6,436.74</b>	<b>27,029.92</b>	<b>3,216.18</b>	<b>2,920.59</b>	<b>2,024.50</b>	<b>9,884.00</b>
<b>2 EXPENSES</b>									
	Changes in inventories of stock-in-trade	-	-	7.47	7.47	-	-	-	-
	Employee benefit expenses	3,959.62	3,865.50	3,607.47	14,946.06	1,428.33	1,186.45	1,014.87	4,321.99
	Finance cost	180.79	210.19	259.81	897.65	27.22	25.24	23.95	109.08
	Depreciation and amortisation expenses	279.03	283.33	282.45	1,126.63	73.07	72.91	74.92	288.58
	Other expenses	1,063.82	1,112.30	1,056.11	3,989.29	269.12	427.83	211.38	1,144.63
	<b>Total expenses</b>	<b>5,483.26</b>	<b>5,471.32</b>	<b>5,213.31</b>	<b>20,967.10</b>	<b>1,797.74</b>	<b>1,712.43</b>	<b>1,325.12</b>	<b>5,864.28</b>
<b>3 Profit before tax (1-2)</b>		<b>1,948.82</b>	<b>1,800.85</b>	<b>1,223.43</b>	<b>6,062.82</b>	<b>1,418.44</b>	<b>1,208.16</b>	<b>699.38</b>	<b>4,019.72</b>
<b>4 Tax Expenses</b>									
	Current tax	572.20	163.97	573.50	1,247.55	245.91	211.57	126.93	700.22
	Deferred tax	(138.77)	158.86	(304.94)	(45.32)	43.78	(1.52)	0.43	0.02
	<b>Total tax Expenses</b>	<b>433.43</b>	<b>322.83</b>	<b>268.56</b>	<b>1,202.23</b>	<b>289.69</b>	<b>210.05</b>	<b>127.36</b>	<b>700.24</b>
<b>5 Profit for the period / year (3-4)</b>		<b>1,515.39</b>	<b>1,478.02</b>	<b>954.87</b>	<b>4,860.59</b>	<b>1,128.75</b>	<b>998.11</b>	<b>572.02</b>	<b>3,319.48</b>

The statutory auditor has digitally signed the statement for identification purpose only and this statement should be read in conjunction with review report dated July 31, 2025.



**Inventurus Knowledge Solutions Limited**  
**Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),**  
**Thane Belapur Road, Airoli, Navi Mumbai - 400 706, Thane, Maharashtra, India.**  
**CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205**  
**Website: www.ikshealth.com Email : investor\_relations@ikshealth.com**  
**Statement of unaudited financial results for the quarter ended June 30, 2025**

(Amounts in INR ₹ Million, unless otherwise stated)

Sr.No	Particulars	Consolidated				Standalone			
		For the quarter ended			For the year ended	For the quarter ended			For the year ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		unaudited	unaudited	unaudited	audited	unaudited	unaudited	unaudited	audited
<b>6</b>	<b>Other Comprehensive Income</b>								
	<i>Items that may be reclassified to profit or loss</i>								
	Gains/ (losses) on cash flow hedges (net)	68.04	179.93	42.62	(39.42)	57.78	156.57	42.62	(40.62)
	Exchange differences on translation of financial statements of foreign operations	19.58	(30.60)	(7.88)	217.59	-	-	-	-
	Income tax relating to above items	(14.84)	(27.77)	(6.70)	6.88	(12.26)	(22.46)	(6.43)	6.88
		<b>72.78</b>	<b>121.56</b>	<b>28.04</b>	<b>185.05</b>	<b>45.52</b>	<b>134.11</b>	<b>36.19</b>	<b>(33.74)</b>
	<i>Items that will not be reclassified to profit or loss</i>								
	Remeasurement of post employment benefit obligations	(14.25)	(2.44)	(4.67)	(18.15)	(8.55)	(2.44)	(2.73)	(13.66)
	Changes in the fair value of equity investments at FVOCI	-	689.35	2.05	691.40	-	-	-	-
	Income tax relating to above items	3.75	(178.72)	0.93	(176.69)	2.32	0.51	0.44	2.54
		<b>(10.50)</b>	<b>508.19</b>	<b>(1.69)</b>	<b>496.56</b>	<b>(6.23)</b>	<b>(1.93)</b>	<b>(2.29)</b>	<b>(11.12)</b>
	<b>Other Comprehensive Income / (loss) for the period / year, net of tax</b>	<b>62.28</b>	<b>629.75</b>	<b>26.35</b>	<b>681.61</b>	<b>39.29</b>	<b>132.18</b>	<b>33.90</b>	<b>(44.86)</b>
<b>7</b>	<b>Total Comprehensive Income for the period / year (5+6)</b>	<b>1,577.67</b>	<b>2,107.77</b>	<b>981.22</b>	<b>5,542.20</b>	<b>1,168.04</b>	<b>1,130.30</b>	<b>605.92</b>	<b>3,274.62</b>
<b>8</b>	<b>Paid-up equity share capital (Face value ₹ 1 per share)</b>		<b>170.23</b>		<b>170.23</b>		<b>170.23</b>		<b>170.23</b>
<b>9</b>	<b>Reserves excluding revaluation reserves as at balance sheet date</b>				<b>17,726.70</b>				<b>12,100.04</b>
<b>10</b>	<b>Earnings per share (Nominal value of share ₹ 1 each)</b>								
	Basic (INR per share)	<b>9.07</b>	<b>8.88</b>	<b>5.75</b>	<b>29.20</b>	<b>6.75</b>	<b>6.00</b>	<b>3.44</b>	<b>19.94</b>
	Diluted (INR per share)	<b>8.85</b>	<b>8.70</b>	<b>5.66</b>	<b>28.62</b>	<b>6.59</b>	<b>5.88</b>	<b>3.39</b>	<b>19.54</b>

The statutory auditor has digitally signed the statement for identification purpose only and this statement should be read in conjunction with review report dated July 31, 2025.

**Inventurus Knowledge Solutions Limited**  
Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),  
Thane Belapur Road, Airoli, Navi Mumbai - 400 706, Thane, Maharashtra, India.  
CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205  
Website: www.ikshealth.com Email: : investor\_relations@ikshealth.com

**Notes to the Statement of Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2025**

- 1 The above standalone financial results of Inventurus Knowledge Solutions Limited ("the Company") and consolidated financial results of the Company and its subsidiaries (collectively "the Group") for the quarter ended June 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on July 31, 2025. The above results for the quarter ended June 30, 2025 have been reviewed by the Statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The figures for the quarter ended June 30, 2024 as reported in the statement have been approved by the Company's Board of Directors but have not been subjected to limited review since the requirement of submission of quarterly financial results is applicable on listing of equity shares of the Company from the quarter ended December 31, 2024.
- 2 The statement has been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder.
- 3 The figures of the quarter ended March 31, 2025 are balancing figures between the audited figures in respect of the full financial year ended on March 31, 2025 and the unaudited published year to date figures upto third quarter ended on December 31, 2024, which were subjected to Limited review by the Statutory Auditors.
- 4 The Group operates in one reportable business segment which comprises a Care enablement platform providing technology enabled solutions to Healthcare providers. This in the context of Indian Accounting Standard (Ind AS 108) "Operating Segments", constitutes a single operating segment.
- 5 During the quarter ended June 30, 2025, the Company has allotted 23,942 shares (previous period : 464,800 shares) to eligible employees on exercise of Employee Stock options, in accordance with the terms and conditions of the IKS Employees Stock Options Plan 2022 named 'IKS Health - ESOP Policy 2022' as approved by the shareholders of the Company on April 22, 2022. Accordingly, the Company has transferred ₹ 3.51 million to the Securities Premium during the quarter ended June 30, 2025. Further, during the quarter ended June 30, 2025, the Company has granted 287,500 stock options to eligible employees, as approved in the Nomination and Remuneration Committee meeting. The related share based compensation expense for the quarter ended June 30, 2025 is ₹ 12.70 million.
- 6 The Board of Directors of the Company at its Meeting held on June 30, 2025, approved investment upto \$ 17,000,000 by Inventurus Knowledge Solutions Inc, a subsidiary of the Company in IKS WWMG MSO LLC ("Target Company") by subscribing upto 17,000,000 Common Units of the Target Company, which will result in acquisition of 48.02% of the outstanding equity interests of the Target Company by Inventurus Knowledge Solutions Inc. The contractual Purchase Closing Date is July 2, 2025 being the date on which Company has made the required payment as per the Purchase closing terms.
- 7 Earnings per share for the interim periods are not annualised.
- 8 The consolidated financial results of the Group include the results of its subsidiary companies viz: Inventurus Knowledge Solutions Inc, IKS Cares Foundation and its step down subsidiary companies viz: Aquity Holdings Inc, Aquity Solutions LLC, Aquity Solutions India Private Limited, Aquity Solutions Australia Pty Limited and Aquity Canada ULC.

PRIYANSHU  
DINESHKUMAR GUNDANA

Digitally signed by PRIYANSHU  
DINESHKUMAR GUNDANA  
Date: 2025.07.31 20:39:17 +05'30'

The statutory auditor has digitally signed the statement for identification purpose only and this statement should be read in conjunction with review report dated July 31, 2025.

Place : Mumbai  
Date : July 31, 2025

**For Inventurus Knowledge Solutions Limited**

**Sachin  
Gupta**

Digitally signed by  
Sachin Gupta  
Date: 2025.07.31  
20:29:24 +05'30'

Sachin K. Gupta  
Whole-Time Director  
DIN - 02239277

## Annexure – B

**Disclosure with respect to the appointment of Mr. Sachin Gupta as an Additional Director (Non-Executive, Non-Independent) of the Company:**

Sr. No.	Particulars	Details
1.	Name of the Director	Mr. Sachin Gupta
2.	Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del>	The Board of Directors has appointed Mr. Sachin Gupta as an Additional Director (Non-Executive, Non-Independent), liable to retire by rotation w.e.f. August 1, 2025, subject to approval of shareholders.
3.	Date of appointment/ <del>cessation (as applicable) &amp; term of appointment</del>	Date of appointment: August 1, 2025 Term of appointment: Liable to retire by rotation.
4.	Brief Profile (in case of appointment)	Mr. Sachin Gupta is a Founder and one of the Promoter of the Company. He is the Global CEO of Inventurus Knowledge Solutions Inc. He holds a bachelor's degree in engineering (computer) from the University of Pune. He is also a member of the Young Presidents' Organisation. He has over 17 years of experience in business management. In the past, he has been associated with Seletica Configurators India Private Limited, Majoris Systems Private Limited and Lionbridge Technologies, Inc. and has prior experience in software and business development.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Sachin Gupta is not related to any of the Directors of the Company.

**Annexure – C**

**Disclosure with respect to the resignation of Mr. Sachin Gupta from the post of Whole-time Director of the Company:**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Name of the Director	Mr. Sachin Gupta
2.	Reason for change viz. <del>appointment,</del> resignation, <del>removal, death or otherwise</del>	Mr. Sachin Gupta has tendered his resignation as a Whole-time Director of the Company, due to his personal reasons.
3.	Date of <del>appointment/</del> cessation (as applicable) & <del>term of appointment</del>	With effect from close of business hours on July 31, 2025.
4.	Brief Profile (in case of appointment)	Not applicable.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable.

July 31, 2025

To,

The Board of Directors  
**Inventurus Knowledge Solutions Limited**  
Building No. 5 & 6, Unit No. 801  
8th Floor, Mindspace SEZ  
Thane Belapur Road  
Airoli, Navi Mumbai – 400 708

Dear Board members,

**Subject:** Resignation from the position of Whole-time Director

I hereby tender my resignation from the position of Whole-time Director of Inventurus Knowledge Solutions Limited (the "Company"), with effect from close of business hours on July 31, 2025 due to personal reasons. It's been an honour and privilege to serve as the Whole-time Director and contribute to the growth and success of the Company.

I hereby confirm that there are no other material reasons for my resignation other than the one mentioned above.

I will be grateful for the trust and confidence reposed in me by the Board and thank the entire Board for their unwavering support throughout my tenure as Whole-time Director of the Company.

I would be honored to continue as a Director of the Company in the capacity of a Non-Executive and Non-Independent Director.

Thanking you,



**Sachin Gupta**

Whole-time Director

DIN: 02239277



## Annexure – E

**Disclosure with respect to the appointment of Ms. Nithya Balasubramanian, CFO (Key Managerial Personnel of the Company), as an Additional Director (Whole-time Director) on the Board of the Company**

Sr. No.	Particulars	Details
1.	Name of the Director	Ms. Nithya Balasubramanian
2.	Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del>	<p>The Board of Directors have appointed Ms. Nithya Balasubramanian as an Additional Director (Whole-time Director), w.e.f. August 1, 2025, subject to approval of shareholders.</p> <p>Ms. Nithya Balasubramanian continued to be Chief Financial Officer of the Company.</p>
3.	Date of appointment/ <del>cessation</del> (as applicable) & term of appointment	<p>Date of appointment: Date of appointment as Additional Director (Whole-time Director) with effect from August 1, 2025.</p> <p>Term of appointment: For a term of 5 years from August 1, 2025 to July 31, 2030 (both days inclusive) subject to approval by the shareholders of the Company.</p>
4.	Brief Profile (in case of appointment)	Ms. Nithya Balasubramanian holds a bachelor's degree of engineering in electrical and electronical engineering from the Birla University of Technology & Science, Rajasthan, and a post graduate diploma in management from Indian Institute of Management, Bangalore. She has over 17 years of experience in the field of corporate finance and equities research. She has previously worked with McKinsey & Company, Inc as their engagement manager, Cipla Limited as their vice president and Alliance Bernstein Business Services Private Limited as their vice president/director, senior research analyst.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Ms. Nithya Balasubramanian is not related to any of the Directors of the Company.



## Annexure - F

**Disclosure with respect to the appointment of Mr. Garheng Albert Kong (DIN: 11218828), as Additional Director (Non-Executive, Independent) on the Board of the Company:**

Sr. No.	Particulars	Details
1.	Name of the Director	Mr. Garheng Albert Kong
2.	Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del>	Appointment of Mr. Garheng Albert Kong (DIN: 11218828), as Additional Director (Non-Executive, Independent) of the Company.
3.	Date of appointment/ <del>cessation (as applicable)</del> & term of appointment	<p>Date of appointment: Date of appointment as Additional Director (Non- Executive, Independent) with effect from August 1, 2025.</p> <p>Term of appointment: For a term of 5 years from August 1, 2025 to July 31, 2030 (both days inclusive) subject to approval by the shareholders of the Company.</p>
4.	Brief Profile (in case of appointment)	<p>Mr. Garheng Albert Kong is a physician, scientist, and engineer by training. He has over two decades of experience investing in innovative healthcare companies with a long list of successes (36 IPO/M&amp;A exits). He founded HealthQuest Capital in 2012 to improve people's lives through improving healthcare on a significant scale. His vision was to build a best-in-class team of the highest talent and integrity to work with outstanding entrepreneurs to transform healthcare through high growth companies while generating outsized risk adjusted returns for investors.</p> <p>His interests and industry footprint are broad as he serves as the Lead Independent Director of LabCorp (LH) and serves on the board of Xeris Biopharma (XERS), Be the Match, Duke University Health System, Duke University Board of Trustees, Dell Children's Foundation, UT President's Commercial Advisory Board, and the Austin Healthcare Council, and has served as Chairman on 11 Boards. He is an Aspen Institute Health Innovators Fellow, Kauffman Fellows Mentor, and member of YPO. Mr. Kong was named a Top 25 Healthcare Investor by Growth Cap in 2022, 2024 and 2025, and received their Healthcare Investor of the Year award for 2024 (presented in March 2025). In 2023, he was also recognized by Board Prospects as one of the Top 30 Asian American and Pacific Islander Board Members in the U.S.</p> <p>He has received undergraduate degrees in both Chemical Engineering and Biological Sciences from Stanford, while on an athletic scholarship. He then earned a MD, PhD and MBA</p>

		from Duke University, graduating at the top of his class in each instance. His early career included stints at GlaxoSmithKline, McKinsey and a medical device start-up, TherOx, before joining Intersouth Partners and then Sofinnova Investments.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Garheng Albert Kong is not related to any of the Directors of the Company.

## Annexure – G

### Disclosure with respect to appointment of Internal Auditor:

Sr. No.	Particulars	Details
1.	Name of the Internal Auditor	M/s. KKC & Associates LLP, Chartered Accountants (Firm Registration Number – 105146W/W100621)
2.	Reason for <del>change viz.</del> appointment, <del>resignation,</del> removal, <del>death</del> or otherwise	Re-appointment of M/s. KKC & Associates LLP, Chartered Accountants, as the Internal Auditors of the Company, for the financial year 2025-26.
3.	Date of appointment/ <del>cessation (as applicable)</del> & term of appointment	Date of appointment: July 31, 2025 for the financial year 2025-26.
4.	Brief Profile (in case of appointment)	KKC & Associates LLP is one of India's leading chartered accountancy firms, with a heritage that dates back to 1936. Over the decades, they have built a strong presence across Mumbai, Bengaluru, Pune, and Ahmedabad, and today, their 350+ professionals and 17 partners proudly support clients ranging from MNCs and large enterprises to high-growth SMEs and owner-managed businesses.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

\*\*\*